{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:26:39Z","timestamp":1792517199758,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Quality Control Department of Formulation of Zhejiang Huahai Pharmaceutical Co. Ltd"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jpba.2019.01.045","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T07:37:19Z","timestamp":1549006639000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Solution degradant of mirabegron extended release tablets resulting from a Strecker-like reaction between mirabegron, minute amounts of hydrogen cyanide in acetonitrile, and formaldehyde in PEG during sample preparation"],"prefix":"10.1016","volume":"168","author":[{"given":"Jinsheng","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianpei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxue","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danna","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenquan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.01.045_bib0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2- [(2-hydroxy-2-phenylethyl)amino]-ethyl}acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2019.01.045_bib0010","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"4","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.jpba.2019.01.045_bib0015","first-page":"98","article-title":"Application of LC-MSn in conjunction with mechanism based stress studies in the elucidation of drug impurity\/degradation product structures and degradation pathways","volume":"1\u20132","author":"Li","year":"2008","journal-title":"Am. Pharm. Rev."},{"key":"10.1016\/j.jpba.2019.01.045_bib0020","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jpba.2009.05.041","article-title":"Use of high resolution LC\u2013MSn analysis in conjunction with mechanism-based stress studies: identification of asarinin, an impurity from sesame oil in an animal health product","volume":"50","author":"Wang","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.01.045_bib0025","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jpba.2008.09.021","article-title":"Application of LC\u2013MSn in conjunction with mechanism-based stress studies in the elucidation of drug impurity structure: rapid identification of a process impurity in betamethasone 17-valerate drug substance","volume":"48","author":"Li","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.01.045_bib0030","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jps.21477","article-title":"Forced degradation of betamethasone sodium phosphate under solid state: formation, characterization, and cechanistic study of all four 17,20-diastereomers of betamethasone 17-deoxy-20-hydroxy-21-oic acid","volume":"98","author":"Li","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2019.01.045_bib0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jpba.2009.04.004","article-title":"Rapid structure elucidation of drug degradation products using mechanism-based stress studies in conjunction with LC\u2013MSn and NMR spectroscopy: identification of a photodegradation product of betamethasone dipropionate","volume":"50","author":"Lin","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.01.045_bib0040","series-title":"Organic Chemistry of Drug Degradation, Chapter 8, Strategies for Elucidation of Degradant Structures and Degradation Pathways","first-page":"227","author":"Li","year":"2012"},{"key":"10.1016\/j.jpba.2019.01.045_bib0045","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1002\/jps.24667","article-title":"Artifacts generated during azoalkane peroxy radical oxidative stress testing of pharmaceuticals containing primary and secondary amines","volume":"104","author":"Nefliu","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2019.01.045_bib0050","series-title":"Organic Chemistry of Drug Degradation, Chapter 5, Drug\u2013Excipient Interactions and Adduct Formation","first-page":"150","author":"Li","year":"2012"},{"key":"10.1016\/j.jpba.2019.01.045_bib0055","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jpba.2005.12.033","article-title":"Simultaneous determination of formic acid and formaldehyde in pharmaceutical excipients using headspace GC\/MS","volume":"3","author":"delBarrio","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.01.045_bib0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1081\/PDT-120030249","article-title":"Influence of formaldehyde impurity in polysorbate 80 and PEG-300 on the stability of a parenteral formulation of BMS-204352: identification and control of the degradation product","volume":"9","author":"Nassar","year":"2004","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jpba.2019.01.045_bib0065","unstructured":"Several case studies on elucidation of \u201cMysterious peaks\u201d by high resolution LC-MS were presented by Bin Chen in an invited oral session at 2012 Eastern Analytical Symposium. One of the studies reported the presence of trace amount of HCN in HPLC grade acetonitrile, which caused on-line degradation of one key impurity that contains an activated aldehyde moiety: \u201cUse of High Resolution LC-MS in Elucidation of Mysterious Peaks caused by Trace Amounts of Impurities in Mobile Phase, HPLC Vials, and Product Samples\u201d http:\/\/www.eas.org\/askeas\/2012%20EAS%20Abstracts.pdf last accessed April 21, 2017."},{"key":"10.1016\/j.jpba.2019.01.045_bib0070","unstructured":"It was disclosed that HCN is a process impurity during the manufacturing of acetonitrile: US Patent 4,308,108 and European Patent Application 83870142.3."},{"key":"10.1016\/j.jpba.2019.01.045_bib0075","doi-asserted-by":"crossref","first-page":"31024","DOI":"10.1039\/C5RA01711D","article-title":"Characterization of stress degradation products of mirabegron using UPLC-QTOF-MS\/MS and in silico toxicity predictions of its degradation products","volume":"5","author":"Kalariya","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2019.01.045_bib0080","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3998\/ark.5550190.0005.412","article-title":"Tetrabutylammonium cyanide catalyzes the addition of TMSCN to aldehydes and ketones","volume":"IV","author":"C\u00f3rdoba","year":"2004","journal-title":"Arkivoc"},{"key":"10.1016\/j.jpba.2019.01.045_bib0085","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1016\/j.ejmech.2011.07.037","article-title":"New aldehyde and vinylsulfone proteasome inhibitors for targeted melanoma therapy","volume":"46","author":"Vivier","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jpba.2019.01.045_bib0090","unstructured":"C. Rajendiran, K. Reddy, J. Venkateswarlu, An improved process for the preparation of 2-(2-aminothazol-4-yl)-N-[4-(2-[[(2R)-2-hydroxy-2-phenylethyl] amino]ethyl)phenyl]acetamide. W.O. patents, 2015,155,664 A1."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518326967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518326967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T21:37:06Z","timestamp":1606340226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518326967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":18,"alternative-id":["S0731708518326967"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.01.045","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Solution degradant of mirabegron extended release tablets resulting from a Strecker-like reaction between mirabegron, minute amounts of hydrogen cyanide in acetonitrile, and formaldehyde in PEG during sample preparation","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.01.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}